ECYT - Endocyte, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.67
+0.06 (+0.25%)
As of 10:42AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close23.61
Open23.62
Bid23.66 x 900
Ask23.67 x 4000
Day's Range23.61 - 23.69
52 Week Range2.81 - 23.89
Volume341,107
Avg. Volume2,828,190
Market Cap1.943B
Beta (3Y Monthly)-1.00
PE Ratio (TTM)N/A
EPS (TTM)-0.96
Earnings DateMay 7, 2018 - May 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.33
Trade prices are not sourced from all markets
  • A Closer Look at Insys Therapeutics’ Performance Year-to-Date
    Market Realist7 days ago

    A Closer Look at Insys Therapeutics’ Performance Year-to-Date

    Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.

  • GlobeNewswire7 days ago

    Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Endocyte (ECYT) Reports Q3 Loss, Tops Revenue Estimates
    Zacks9 days ago

    Endocyte (ECYT) Reports Q3 Loss, Tops Revenue Estimates

    Endocyte (ECYT) delivered earnings and revenue surprises of -6.25% and 330.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press9 days ago

    Endocyte: 3Q Earnings Snapshot

    On a per-share basis, the West Lafayette, Indiana-based company said it had a loss of 17 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • GlobeNewswire9 days ago

    Endocyte Provides Third Quarter 2018 Financial Results and Operational Update

    Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced financial results for the third quarter ended Sept. 30, 2018 and provided an operational update. “177Lu-PSMA-617’s value as a potential treatment for patients with mCRPC has been reinforced in both our regulatory interactions and our entry into a merger agreement with Novartis AG, along with our longstanding interactions with patients and physicians in the prostate cancer community,” said Mike Sherman, president and CEO of Endocyte. Announced on October 18, 2018, our entry into an agreement and plan of merger with Novartis AG (Novartis), subject to the terms and conditions of which Novartis will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.

  • Reuters14 days ago

    Bayer CEO backs group's diversified structure

    Bayer's (BAYGn.DE) chief executive reaffirmed his support for a corporate structure made up of healthcare, crop science and animal health businesses, after analysts called for a breakup to shore up its flagging share price. Shares in drugmaker Bayer, which bought Monsanto for $63 billion (£48.4 billion) , have lost more than 25 percent since a U.S. jury in August found its glyphosate-based weedkillers responsible for a man's terminal cancer, with more than 8,700 plaintiffs also seeking damages. "We have announced our strategy in September 2014, which has not changed to date," Chief Executive Werner Baumann told journalists in St. Louis at the former Monsanto headquarters where Bayer's seed business is now based.

  • Reuters14 days ago

    Bayer CEO backs group's diversified structure

    Bayer's chief executive reaffirmed his support for a corporate structure made up of healthcare, crop science and animal health businesses, after analysts called for a breakup to shore up its flagging share price. Shares in drugmaker Bayer, which bought Monsanto for $63 billion, have lost more than 25 percent since a U.S. jury in August found its glyphosate-based weedkillers responsible for a man's terminal cancer, with more than 8,700 plaintiffs also seeking damages. "We have announced our strategy in September 2014, which has not changed to date," Chief Executive Werner Baumann told journalists in St. Louis at the former Monsanto headquarters where Bayer's seed business is now based.

  • PR Newswire14 days ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Endocyte, Inc. - ECYT

    NEW YORK , Nov. 1, 2018 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...

  • Zacks.com featured highlights include: Lamb Weston, Dollar General, Endocyte and CONSOL
    Zacks21 days ago

    Zacks.com featured highlights include: Lamb Weston, Dollar General, Endocyte and CONSOL

    Zacks.com featured highlights include: Lamb Weston, Dollar General, Endocyte and CONSOL

  • This tiny biotech spun a quick $2 billion from $12 million
    MarketWatch25 days ago

    This tiny biotech spun a quick $2 billion from $12 million

    Endocyte licensed a prostate cancer drug a year ago for an upfront payment of $12 million. Now, it’s being bought by the Swiss pharma giant Novartis for more than $2 billion.

  • Can The Uptrend Continue for Endocyte (ECYT)?
    Zacks28 days ago

    Can The Uptrend Continue for Endocyte (ECYT)?

    Investors certainly have to be happy with Endocyte, Inc. (ECYT) and its short term performance.

  • Benzinga28 days ago

    The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 18) Endocyte, Inc. (NASDAQ: ECYT )( announced a deal to ...

  • ACCESSWIRE28 days ago

    Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Endocyte

    NEW YORK, NY / ACCESSWIRE / October 19, 2018 / Shares of biotech stocks Proteostasis Therapeutics and Endocyte were seeing big gains on different exciting announcements. Proteostasis announced encouraging preliminary results while traders learned that Endocyte will be purchased by Novartis for $2.1 billion. Proteostasis Therapeutics, Inc. shares closed up 447.62% on Thursday on skyrocket volume of about 94 million shares.

  • The Wall Street Journal29 days ago

    [$$] Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion

    Novartis AG on Thursday said it would pay $2.1 billion for Endocyte Inc., a U.S. company developing a new treatment for prostate cancer, the Swiss pharmaceutical giant’s latest move to double down on high-value prescription drugs. Endocyte specializes in so-called radiopharmaceuticals, a new class of drug that carries radioactive substances directly to cancer cells so they can kill tumor cells at close range. Novartis agreed to pay $24 a share for the company.

  • Stocks plunge, Dow falls 327 points
    Yahoo Finance29 days ago

    Stocks plunge, Dow falls 327 points

    All three of the major indices sold off into the close on Thursday, and the selling accelerated midday after Treasury Secretary Steven Mnuchin announced that he will not be attending a summit in Saudi Arabia.

  • Endocyte's $2.1 Billion Deal Rewards Investors Who Stuck It Out
    Bloomberg29 days ago

    Endocyte's $2.1 Billion Deal Rewards Investors Who Stuck It Out

    Endocyte rallied more than 1,600 percent in the past 13 months as it advanced its prostate drug candidate -- climaxing on Thursday as Novartis splashed out $2.1 billion on a friendly buyout. The deal came at a 54 percent premium to Wednesday’s close and rewarded a group of sector specialist funds that made big bets on Endocyte, a small Indiana-based drugmaker that’s faced down concern its drug might not be ready for prime time. The biggest winner was apparently VenBio Select Advisor LLC, known for making bets across the drug discovery landscape and the largest holder with more than 7 percent of Endocyte as of the latest filing period ended June 30.

  • Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 Billion
    GuruFocus.com29 days ago

    Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 Billion

    Expanding further into the increasingly competitive field of oncology, Swiss drugmaker Novartis AG (NVS) announced on Thursday morning it is buying biopharmaceutical company Endocyte Inc. (ECYT) in a deal valued at $2.1 billion. Warning! GuruFocus has detected 3 Warning Signs with NVS. According to the terms of the all-cash agreement, Novartis will pay $24 per share for the West Lafayette, Indiana-based company, a 54% premium to the stock's closing price on Oct. 17.

  • The Wall Street Journal29 days ago

    [$$] These Guys Should Start a Hedge Fund

    How do you earn an investment return that would make even the luckiest bitcoin speculator blush? Biotech company Endocyte has the answer.

  • Novartis Gets Key Therapy -- For Almost 200 Times Its Last Price
    Bloomberg29 days ago

    Novartis Gets Key Therapy -- For Almost 200 Times Its Last Price

    On Thursday, Novartis AG agreed to pay almost 200 times that amount for the drug’s current owner, Endocyte Inc. The experimental therapy is the centerpiece of Novartis’s $2.1 billion planned takeover of U.S.-based Endocyte. It pairs tumor-killing radiation with molecules that target diseased cells, and Novartis Chief Executive Officer Vas Narasimhan says it has blockbuster potential.

  • Why Endocyte, Inc. Stock Is Soaring Today
    Motley Fool29 days ago

    Why Endocyte, Inc. Stock Is Soaring Today

    Novartis continues its pivot toward specialized medicines by acquiring Endocyte.

  • TheStreet.com29 days ago

    Novartis Secures Prostate Cancer Treatment With Endocyte Deal

    The deal values the developer of cancer treatments at $24 a share, a 54% premium to Endocyte's closing price on Wednesday of $15.56. Novartis will get its hands on Endocyte's promising Lu-PSMA-617, a radioligand treatment that targets prostate cancer by attaching radioactive Lutetium to cancerous cells. "The proposed acquisition of Endocyte builds on our growing capability in radio-pharmaceuticals, which is expected to be an increasingly important treatment option for patients and a key growth driver for our business," said Novartis Oncology CEO Liz Barrett in a statement.

  • Benzinga29 days ago

    Novartis To Buy Endocyte In $2.1B Deal

    Endocyte, Inc. (NASDAQ: ECYT ) on Thursday  announced  its $2.1-billion cash sale to Novartis AG (NYSE: NVS ). The deal values Endocyte at $24 per share, representing a 54-percent premium from the firm’s ...

  • Exclusive: Walmart set to deliver more products with high-tech help
    Yahoo Finance29 days ago

    Exclusive: Walmart set to deliver more products with high-tech help

    Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.

  • Benzinga29 days ago

    The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 17) Anixa Biosciences Inc (NASDAQ: ANIX ) Down In The Dumps ...

  • Novartis buying cancer drug maker Endocyte for $2.1B
    Yahoo Finance Video29 days ago

    Novartis buying cancer drug maker Endocyte for $2.1B

    A big deal for drug maker Novartis. It’s buying cancer pharma company Endocyte for $2.1B. Yahoo Finance’s Alexis Christoforous, Scott Gamm and Julia La Roche have more.